
|Articles|February 1, 2004
Blue light-filtering IOL option for cataract surgery
Anaheim, CA-Although longer follow-up is needed to determine whether the pseu-dophakic, blue light-filter-ing IOL (AcrySof Natural, Alcon) reduces the risk of progression of age-related macular degeneration (AMD), available indirect evidence provides sufficient sup-port to advocate its use in cataract surgery, said Robert J. Cionni, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
2
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
3
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal
4
Q&A: Understanding Medicare payment shifts in eye care
5














































